Mivavotinib

**Semantic type:** Pharmacologic Substance

**Definition:** An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.

**Synonyms:** - 3H-Pyrrolo(3,4-C)pyridin-3-one, 6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)- - MIVAVOTINIB - Spleen Tyrosine Kinase Inhibitor TAK659 - TAK-659 Free Base - TAK659 Free Base - syk Inhibitor TAK-659 - syk Inhibitor TAK659 - syk-Inhibitor TAK-659 - syk-Inhibitor TAK659